Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism

Research output: Contribution to journalArticleAcademicpeer-review

40 Downloads (Pure)

Abstract

Background: Patients with autosomal dominant polycystic kidney disease (ADPKD) are treated with a vasopressin V2 receptor antagonist (V2RA) to slow disease progression. This drug increases vasopressin considerably in these patients with already elevated baseline levels. Vasopressin is known to stimulate the hypothalamic-pituitary-adrenal (HPA) axis through V1 and V3 receptor activation. It is unknown whether this increase in vasopressin during V2RA treatment affects glucocorticoid production. Methods: Twenty-seven ADPKD patients were studied on and off treatment with a V2RA and compared to age- and sex-matched healthy controls and IgA nephropathy patients, the latter also matched for kidney function. Vasopressin was measured by its surrogate copeptin. Twenty-four-hour urinary excretions of cortisol, cortisone, tetrahydrocortisone, tetrahydrocortisol, allotetrahydrocortisol, and the total glucocorticoid pool were measured. Results: At baseline, ADPKD patients demonstrated a higher copeptin concentration in comparison with healthy controls, while urinary excretion of cortisol and cortisone was lower (medians of 0.23 vs. 0.34 mu mol/24 h, p = 0.007, and 0.29 vs. 0.53 mu mol/24 h, p <0.001, respectively). There were no differences in cortisol and cortisone excretion compared to IgA nephropathy patients. Cortisol, cortisone, and total glucocorticoid excretions correlated with kidney function (R = 0.37, 0.58, and 0.19, respectively; all p <0.05). Despite that V2RA treatment resulted in a 3-fold increase in copeptin, only cortisone excretion increased (median of 0.44 vs. baseline 0.29 mu mol/24 h, p <0.001), whereas no changes in cortisol or total glucocorticoid excretion were observed. Conclusions: Increased concentration of vasopressin in ADPKD patients at baseline and during V2RA treatment does not result in activation of the HPA axis. The impaired glucocorticoid production in these patients is related to their degree of kidney function impairment.

Original languageEnglish
Article number000511000
Pages (from-to)861-870
Number of pages10
JournalAmerican Journal of Nephrology
Volume51
Issue number11
Early online date4-Nov-2020
DOIs
Publication statusPublished - Dec-2020

Keywords

  • Autosomal dominant polycystic kidney disease
  • V2 receptor antagonist
  • Cortisol
  • Glucocorticoid metabolites
  • POLYCYSTIC KIDNEY-DISEASE
  • URINARY FREE CORTISOL
  • LONG-TERM STABILITY
  • 11-BETA-HYDROXYSTEROID DEHYDROGENASE
  • ARGININE-VASOPRESSIN
  • TOLVAPTAN
  • TYPE-2
  • METABOLISM
  • MODULATION
  • SECRETION

Cite this